Turkish Journal of Medical Sciences
Volume 40

Number 4

Article 23

1-1-2010

Thyroid hormone reference intervals and the prevalence of thyroid
antibodies
AYDAN ÇELEBİLER
SİBEL BİLGİLİ
EMİNE ÖMÜR ERKIZAN
HURİYE SERİN
MUHAMMET BAYSAL KARACA

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
ÇELEBİLER, AYDAN; BİLGİLİ, SİBEL; ERKIZAN, EMİNE ÖMÜR; SERİN, HURİYE; and KARACA, MUHAMMET
BAYSAL (2010) "Thyroid hormone reference intervals and the prevalence of thyroid antibodies," Turkish
Journal of Medical Sciences: Vol. 40: No. 4, Article 23. https://doi.org/10.3906/sag-0906-62
Available at: https://journals.tubitak.gov.tr/medical/vol40/iss4/23

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Original Article

Turk J Med Sci
2010; 40 (4): 665-672
© TÜBİTAK
E-mail: medsci@tubitak.gov.tr
doi:10.3906/sag-0906-62

Thyroid hormone reference intervals and the prevalence of
thyroid antibodies
Aydan ÇELEBİLER ÇAVUŞOĞLU, Sibel BİLGİLİ, Ömür ERKIZAN, Huriye ARICAN, Baysal KARACA

Aim: To establish new reference intervals for thyrotropin (TSH), free thyroxine (FT4), and free triiodothyronine (FT3)
on the Beckman Coulter DxI 800 in healthy Turkish adults and assess the prevalence of laboratory evidence of thyroid
antibodies in this population.
Materials and methods: Specimens were obtained from 619 healthy volunteers (338 females, 281 males).The study was
conducted with health care professionals and their relatives, The mean age of all the subjects was 34.7 and the median
was 31 years, with ages ranging from 15 to 84. Moreover, the subjects had no evidence of thyroid autoimmunity or a
history of drug use, both of which might interfere with thyroid function.
Results: After exclusion of samples positive for thyroid antibodies (Antithyroperoxidase; TPOAb, Antithyroglobulin;
TgAb), the final sample size for the evaluation of TSH, FT3, and FT4 reference ranges was 509 (254 females, 255 males)
and the age range was 15-80 (mean 34.1, median 30). The prevalence of antithyroid antibodies was 17.8% in total and
positive thyroid antibodies were more common among females (13.6%) than males (4.2%). We established the reference
intervals for the healthy adults as 0.41-4.25 mIU/L for TSH, 0.61-1.06 ng/dL (7.85-13.64 pmol/L) for FT4, and 2.62-3.84
pg/mL (4.02-5.90 pmol/L) for FT3.
Conclusion: The reference intervals of thyroid hormones vary considerably from those of other populations and the
intervals recommended by the manufacturer. This underlines the need for population-specific reference ranges.
Key words: Reference intervals, thyroid antibodies, thyrotropin, free thyroxine, free triiodothyronine

Tiroid hormon referans aralıkları ve tiroid antikor prevalansı
Amaç: Bu çalışmanın amacı sağlıklı Türk yetişkinlerinde Beckman Coulter DxI 800 analizöründe tirotropin (TSH),
serbest tiroksin (FT4) ve serbest triiodotironin (FT3) için yeni referans aralıklarını ve bu populasyondaki tiroid
antikorlarının prevalansını belirlemektir.
Yöntem ve gereç: Örnekler tiroid fonksiyonlarını etkileyebilecek ilaç kullanımı, tiroid otoimmunitesi hikayesi
bulunmayan, yaşları 15-84 (ortalama 34,7, medyan 31) arası olan sağlıklı 619 (338 kadın, 281 erkek) gönüllü sağlık
çalışanı ve yakınlarından elde edildi.
Bulgular: Tiroid antikorları (Antitiroperoksidaz; TPOAb, Antitiroglobulin; TgAb) pozitif olan örnekler çalışma dışı
bırakıldıktan sonra, TSH, FT3, FT4 referans aralıkları yaşları 15-80 (ortalama 34,1, medyan 30) arasında olan 509 (254
kadın, 255 erkek) örnekle değerlendirildi. Antitiroid antikorların varlığı kadınlarda (% 13,6) erkeklerden (% 4,2) daha
yüksek olmak üzere toplamda % 17,8 olarak tespit edildi. Sağlıklı yetişkinlerde yeni referans aralıkları TSH için 0,41-4,25
mIU/L, FT4 için 0,61-1,06 ng/dL (7,85-13,64 pmol/L) ve FT3 için 2,62-3,84 pg/mL (4,02-5,90 pmol/L) olarak bulundu.
Sonuç: Bu çalışmada, tiroid hormonlarının referans aralıkları bir populasyondan diğerine göre ve üretici firmanın
önerdiği değerlere göre farklılık göstermiştir. Bu da populasyona özgü referans aralıklarının belirlenmesinin gerekli
olduğunun önemini belirtir.
Anahtar sözcükler: Referans aralıkları, tiroid antikorları, tirotropin, serbest tiroksin, serbest triiyodotironin
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Introduction
Reference ranges vary considerably from one
laboratory to another and are dependent on the
population, diet, methodology, and selection of
reference group or needs of the clinics (1). For
the determination of reference ranges, the most
important stage is the selection of the reference
group and the standardization of preanalytical
factors (2,3). The Clinical Laboratory Standards
Institute (CLSI, formerly known as NCCLS)
recommends non-parametric methods, while the
International Federation of Clinical Chemistry
and Laboratory Medicine (IFCC) recommends
both non-parametric methods and parametric
methods for the determination of reference
ranges (1,2,4).
Biochemical examination of the thyroid function
by using the measurement of thyrotropin (TSH) and
thyroid hormones (free thyroxine (FT4) and free
triiodothyronine (FT3)) in serum is an everyday task
in most clinical biochemical laboratories. Thyroid
hormone levels are known to be influenced by a
variety of factors, including diet, genetics, and the
presence of thyroid autoimmunity. Reference
intervals provided by assay manufacturers are
representative data and may not always be appropriate
for different locations and patient demographics.
According to the results from the National Health
and Nutrition Examination Survey (NHANES)
studies on regular thyroid function (5), the National
Academy of Clinical Biochemistry (NACB) proposed
that when establishing new TSH reference intervals
only euthyroid healthy volunteers be included, who
should be free from detectable autoantibodies against
thyroid peroxidase (TPOAb) or thyroglobulin (TgAb)
and any personal or family history of thyroid
dysfunction (6).
The aims of the present study were: 1) to establish
thyroid hormone reference intervals in healthy
Turkish adults without evidence of thyroid
autoimmunity on the DxI 800 instrument, and 2) to
assess the prevalence of laboratory evidence of thyroid
antibodies in this population.
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Materials and methods
Subjects
According to the CLSI C28-A standard, we
prepared a questionnaire for determining exclusion
criteria and preanalytic factors (7). Specimens were
obtained from healthy volunteers, all of whom were
healthcare professionals and their relatives. The
subjects were adults with no visible goiter, no personal
or family history of thyroid dysfunction, and on no
medication that might interfere with thyroid function.
Furthermore, their fasting blood glucose, urea,
creatinine, AST, ALT, total cholesterol triglyceride,
HDL and LDL cholesterol, complete blood count, and
sedimentation levels were normal. The study was
approved by the local ethical committee.
Assay methods
Samples were collected at 0900-1000 after an
overnight fast into vacutainer tubes with gel.
Centrifugation was performed within 1 h at 1500 × g
for 10 min and samples were analyzed immediately.
Analyses of TSH, FT3, FT4, TPOAb, and TgAb
were performed on an automated immunoassay
system (DxI 800, Beckman Coulter) using a direct
chemiluminescence detection system according to the
manufacturer’s instructions. The TSH assay is a 2 site
immunometric (sandwich) assay whereas the FT3 and
FT4 assays are competitive assays with FT4 being
measured in 2-step free-analyte assay format and FT3
in an analog-type free analyte assay format.
The measurements were made using the same
reagents and the same instruments for all patients.
TPOAb and TgAb levels above the 9 and 4 IU/mL
respectively were regarded as positive according to the
manufacturer’s data.
Assay imprecision was assessed by the use of
commercial quality-control materials, Liquicheck
levels 1-3 (Bio-Rad) and Mass Liquimmune levels 13 (Microgenics). Each control material was analyzed
in duplicate per run. Daily runs were performed 5
days a week over 3 weeks for a total of 30 replicates
for each control.
Statistical analysis
Reference values were determined in accordance
with the protocols published by the Expert Panel on
the Theory of Reference Values of the IFCC and the
CLSI (2,7,8).
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Gender dependency of thyroid hormone
concentrations was confirmed by the Mann-Whitney
U test. P values < 0.05 were defined as statistically
significant. Gender specific reference limits and
confidence intervals were examined. The relationship
between the thyroid hormones and TPOAb and TgAb
were examined by correlation analysis. All
calculations were performed with MedCalc 9
software.
Results
In total, 619 specimens were included; the age
range was between 15 and 84 (mean 34.7, median 31):
338 female, 281 male. Of these 110 specimens
(17.8%), 84 females and 26 males (age range 18-84;
mean 37.4, median 35) were excluded from the study
because TPOAb and/or TgAb values were positive.

Elevated TgAb and TPOAb frequencies according
to the gender are shown in Table 1 and distributions
according to age are shown in Figure 1.
There was no association between TSH and a
positive TgAb alone; however, a significant correlation
was found between TPOAbs and TSH concentrations
(r: 0.394, P: 0.000).
Figure 2 shows the prevalence of thyroid
antibodies across TSH intervals. The prevalence of the
lowest thyroid antibodies (<20.7%) was seen in a TSH
range between 0.42 and 3.50 mIU/L. The prevalence
of thyroid antibodies progressively increased with
TSH above 2.00 mIU/L, approaching 80% when TSH
was above 5 mIU/L.
The final sample size for the evaluation of FT3 and
FT4 was 509 and the age range was 15-80 (mean 34.1,
median 30); 254 females, 255 males.
For TSH 4 outliers (above the 4.95 mIU/L) were
removed by the Block procedure and the study
continued with 505 specimens. Neither original values
nor log-transformed values were normally distributed
(Kolmogorov-Smirnov test: P < 0.0001).
10
Antibodies positivity (%)

TSH, FT3, and FT4 distributions were calculated
by using Kolmogorov-Smirnov tests. Reference
intervals as well as reference limits were estimated via
percentiles of distributions if distribution (or its
transformation, e.g. via log-function) was not
normally distributed. In that case, lower and upper
2.5th and 97.5th percentiles of distribution were used
to estimate reference limits. If distributions (or its
transformation, e.g. via log-function) did not deviate
from normal distribution, normal distribution
(position of cumulative probabilities) was used to
calculate reference limits. For this analysis, both
approaches were used depending on the properties of
distribution. The Dixon and Block procedures were
used to identify outliers (9,10). Confidence intervals
were calculated according to binomial distribution
(11).

Male
8

Female

6
4
2
0

≤ 20

21-30

31-40
41-50
Age

51-60

≥ 61

Figure 1. TgAb, TPOAb distributions according to age.

Table 1. Elevated thyroid antibodies distributions according to gender.
Gender
Antibodies

TgAb
TPOAb
TgAb and TPOAb
TgAb or TPOAb

Total
Male

Female

7 (1.1%)**
14 (2.3%)**
5 (0.8%)**
26 (4.2%)**

29 (4.7%)*
29 (4.7%)**
26 (4.2%)**
84 (13.6%)**

36 (5.8%)**
43 (6.9%)**
31 (5%)**
110 (17.8%)**

* % within gender, ** % within total
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Thyroid antibodies positivity (%)
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5.00<

TSH (mIU/L)

Figure 2. The prevalence of thyroid antibodies across TSH intervals.

The 97.5th and 2.5th percentile values of upper
and lower reference limits of TSH, FT4, and FT3
together with the 90% confidence intervals are shown
in Table 2.

There were no gender specific differences between
the FT4 serum concentrations. Nevertheless, there
were significant differences in the TSH (P: 0.000) and
FT3 serum concentrations (P: 0.000). There were
gender specific differences in both the upper and
lower reference limits of TSH and FT3 and these are
shown in Table 3. The confidence intervals of the
gender specific reference limits overlap.

There was a correlation between the FT4 and TSH
(r: –0.096, P: 0.031) and FT3 (r: 0.184, P: 0.000), and
also between age and TSH (r: –0.168, P: 0.000) and
FT3 (r: –0.231, P: 0.000).

Intra and interassay imprecisions (n = 20) were
<6.4% for TSH (concentrations, 0.24 mIU/L, 13.5
mIU/L, and 21.8 mIU/L), <4.7% for FT3
(concentrations, 1.54 pg/mL, 2.86 pg/mL, and 5.01

For FT3 and FT4 there were no outliers according
to either the Dixon or the Block procedure. FT3 and
FT4 distributions for all subjects were log-normal.

Table 2. Descriptive analysis and reference limits of thyroid function tests.
Variable

TSH (mIU/L)

FT4 (ng/dL)

FT3 (pg/mL)

Sample size
Lowest value
Highest value
Geometric mean
Median
Coefficient of Skewness
Coefficient of Kurtosis
Significance test for normal distribution
Method of 95th reference limits (double sided)
Lower limit
90% Confidence interval
Upper limit
90% Confidence interval

505
0.04
4.95
1.4620
1.5400
-1.1882 (P < 0.0001)
3.9435 (P < 0.0001)
P < 0.0001*
non-parametric
0.41
0.22 to 0.48
4.25
3.87 to 4.46

509
0.4900
1.3800
0.7996
0.8000
0.0172 (P = 0.8726)
0.5286 (P = 0.0357)
P = 0.1087**
parametric
0.61
0.60 to 0.62
1.06
1.04 to 1.07

509
2.2400
4.2300
3.1720
3.1700
-0.0649 (P = 0.5462)
0.3088 (P = 0.1705)
P = 0.3259**
parametric
2.62
2.59 to 2.65
3.84
3.79 to 3.88

*reject normality ** accept normality
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Table 3. TSH and FT3 reference intervals according to gender.
TSH (mIU/L)
Variable
Gender
Sample size
Lowest value
Highest value
Geometric mean
Median
Coefficient of Skewness
Coefficient of Kurtosis
Significance test for normal distribution
Method of 95th reference limits (double sided)
Lower limit
90% Confidence interval
Upper limit
90% Confidence interval

FT3 (pg/mL)

Male

Female

Male

Female

252
0.04
4.54
1.31
1.37
-1.41(P < 0.0001)
4.93 (P < 0.0001)
P < 0.0001*
non-parametric
0.32
0.11 to 0.48
3.38
3.15 to 4.05

253
0.09
4.95
1.63
1.69
-0.98
2.82
P < 0.0001*
non-parametric
0.44
0.19 to 0.65
4.45
4.14 to 4.84

255
2.24
4.23
3.26
3.25
-0.30 (P: 0.0537)
0.76 (P: 0.0393)
P: 0.0186*
non-parametric
2.69
2.41 to 2.80
3.89
3.82 to 4.03

254
2.37
3.89
3.08
3.10
-0.02 (P: 0.8769)
0.22 (P: 0.4176)
P: 0.7114**
parametric
2.60
2.56 to 2.64
3.66
3.60 to 3.72

*reject normality ** accept normality

pg/mL), <5.2% for FT4 (concentrations, 0.45 ng/mL,
1.27 ng/mL, and 1.98 ng/mL), <5.7% for TgAb
(concentrations, 54.7 IU/mL, 183 IU/mL, and 448
IU/mL), and <6.8% for TPOAb (concentrations, 5.20
IU/mL, 57.6 IU/mL, and 115 IU/mL).
Discussion
This study provides new reference intervals for
TSH, FT3, and FT4 in healthy euthyroid Turkish
adults free from detectable autoantibodies using the
Beckman DxI platform. Clinical reference intervals in
a population are necessary in order to accurately
assess potential thyroid disease. Common practice in
Turkey, both in hospitals and research laboratories, is
to use the manufacturer’s ranges for a given clinical
laboratory assay system. Many of these assay systems
are procured from Europe or the United States and
use reference values based on their populations,
which may not be representative of the Turkish
population. A small number of publications address
reference values in Turkey (12,13), but these are
limited in scope to thyroid function parameters.
This study found that the prevalence of antithyroid
antibodies (TPOAb and/or TgAb) was higher in
Western Anatolia than in Europe and the United States
(5,14-20). In another study, from the Eastern Black Sea
Region in Anatolia (21), Baştemir et al. demonstrated

athyroid antibody prevalence similar to our study.
However, the positive antibody group had a high
frequency of hyperthyroidism, whereas in our study the
positive antibody group had more hypothyroidism.
Some of the differences in thyroid function are related
to differences in iodide intake. In the Eastern Black Sea
region, iodide insufficiency was common (they
frequently eat collard); because of this iodide
supplementation is given as a preventative therapy and
since then an increase in thyroid antibody prevalence
has been seen. In Western Anatolia, nutrition habits are
different and depend more on olive oil. Since increased
iodine intake may enhance thyroid autoimmunity,
regional data may be helpful as a guide for public health
policy about iodide usage; however, prospective studies
will be needed to confirm this. Erdoğan et al. evaluated
the current nationwide iodine status in Turkey by
determining urinary iodine concentrations (UIC) and
household salt iodine content. They showed that
moderate to severe iodine deficiency still exists in
27.8% of the Turkish population (median UIC was 147
μg/L in urban and 42 μg/L in suburban and rural areas),
which is much better when compared with previous
years. Iodine deficiency has been eliminated in most of
the urban population, but it is still an important
problem in rural areas and in particular geographical
regions. Therefore, we think that iodine deficiency does
not exist in our region (22).
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In contrast to other studies that found the
prevalence of antithyroid antibodies increased with
increasing age, we found antibody prevalence higher
in a younger age group, in which females and males
were between 21 and 30 years old. However, we
determined higher antibody levels in females than
males and this agreed with other studies. These results
may be explained by differences in ethnicity,
population, or geographic derived covariates such as
lifestyle, salt iodination, and nutrition.
Both the 2.5th and 97.5th percentiles of our new
reference intervals for FT3 and FT4 were slightly
different from the previous studies (23-25). No
significant differences were observed for the
concentration of FT4 in males and females, whereas
TSH and FT3 levels exhibited significant differences
between females and males. However, because of the
overlapping confidence interval of the reference
limits, gender specific reference limits were not used.
The reference interval for TSH (0.41-4.25 mIU/L)
found in this study was different from the ranges
suggested by Beckman Coulter (0.34-5.60 mIU/L) and
from some previously published studies (18,23,26).
The NHANES III study reported a TSH reference
interval of 0.45 to 4.12 mIU/L (5). TSH serum levels
showed a skewed distribution with a relatively long
‘tail’ towards higher TSH levels. It has been argued
that subjects belonging to this ‘tail’ (with TSH levels
2.5 mIU/L) still have subclinical thyroid disease,
which might have been detected by the use of thyroid
ultrasound and more sensitive assays of thyroid
antibodies; thus the ‘true’ upper normal limit of TSH
would be 2.5 mIU/L (27). While our subjects were
screened for the presence of a visible goiter, no
palpation for the presence of a goiter was carried out,
nor were any thyroid ultrasound studies performed;
this may be a limitation of this study. However,
specimens with positive TPOAb and/or TgAb were
excluded from the study. In Germany, 453 healthy
blood donors with ultrasonographically assessed
normal thyroid glands had TSH reference interval of
0.40-3.77 mIU/L (26). In a Danish study with 3174
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participants, a TSH reference range of 0.40-3.6 mIU/L
was found (28), and a recent large Danish study
defined the upper normal limit of TSH as 4.5 mIU/L
(29). Interestingly, in our study we established 20%
positivity of thyroid antibodies when TSH levels were
below 0.42 mIU/L and above 3.01 mIU/L and 40%
positivity when TSH levels were below 0.16 mIU/L
and above 3.51 mIU/L. The possible consequences of
the use of a TSH concentration < 4.5 mIU/L for
therapeutic interventions to prevent clinical
manifestation of hypothyroidism are still being
discussed (30-32). There is still dispute about the
benefits of treating subclinical hypothyroidism with
levothyroxine when the serum TSH is below 10
mIU/L (33), and there are no accurate data about the
effect of levothyroxine when serum TSH levels are in
the range of 2.5 and 4.0 mIU/L (34). Lowering the
upper limit of normal serum TSH levels from 4-5
mIU/L to 2.5 mIU/L will also substantially increase
the risk of thyroxine overtreatment, resulting in the
well-known and evidence-based risks of subclinical
hyperthyroidism (31). As a result, we suggest follow
up of patients according to their clinical status who
have TSH values between 3.0 and 4.5 mIU/L and may
possibly have the very earliest stage of
hypothyroidism.
In conclusion, we have established reference
intervals for TSH, FT4, and FT3 and found the
prevalence of antithyroid antibodies in sera in our
population. There is no indication for gender
dependence for TSH, FT3, and FT4 reference
intervals in healthy individuals. We suggest that there
is a need for country-specific reference ranges.
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